Does oral lansoprazole really reduce gastric acidity in VLBW premature neonates?

Med J Malaysia. 2012 Jun;67(3):284-8.

Abstract

Premature neonates of very low birth weight (VLBW) whose treatment required the use of naso-gastric tube feeding were investigated. 10 infants suspected of having GERD (gastroesophageal reflux) received oral lansoprazole therapy by tube administration. 9 other infants formed a control group. In the treated group a fasting pH was determined before treatment and again after 7 days treatment. The control group was similarly assessed at an interval of 7 days. Despite acid reduction, the post-treatment pH mean of 1.31 would continue to pose a threat to the esophageal mucosa. The physiology of neonatal acid secretion is discussed to explain these findings.

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles / pharmacology
  • 2-Pyridinylmethylsulfinylbenzimidazoles / therapeutic use*
  • Anti-Ulcer Agents / pharmacology
  • Anti-Ulcer Agents / therapeutic use*
  • Female
  • Gastric Acid / chemistry
  • Gastric Acid / metabolism*
  • Gastroesophageal Reflux / drug therapy*
  • Gastroesophageal Reflux / physiopathology
  • Humans
  • Hydrogen-Ion Concentration / drug effects
  • Infant, Newborn
  • Infant, Premature, Diseases / drug therapy*
  • Infant, Premature, Diseases / physiopathology
  • Infant, Very Low Birth Weight
  • Lansoprazole
  • Male

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Ulcer Agents
  • Lansoprazole